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Abstract
Background: Tumor susceptibility gene 101 (TSG101) was initially identified in fibroblasts as a tumor suppressor
gene but subsequent studies show that TSG101 also functions as a tumor-enhancing gene in some epithelial tumor
cells. Although previous studies have unraveled diverse biological functions of TSG101, the precise mechanism by
which TSG101 is involved in carcinogenesis and tumor progression in a bidirectional and multifaceted manner
remains unclear.
Methods: To reveal the mechanism underlying bidirectional modulation of cell invasion by TSG101, we used RNA
interference to examine whether TSG101 depletion bidirectionally modulated matrix metalloproteinase (MMP)-9
expression in different cell types.
Results: TSG101 depletion promoted cell invasion of HT1080 cells but contrarily reduced cell invasion of HeLaS3
cells. In HT1080 cells, TSG101 depletion increased both baseline and phorbol 12-myristate 13-acetate (PMA)-induced
MMP-9 secretion through enhancing MMP-9 mRNA expression, but did not affect the expression or activation of
MMP-2. In contrast, TSG101 depletion decreased PMA-induced MMP-9 secretion through reducing MMP-9 mRNA
expression in HeLaS3 cells. TSG101 depletion had little impact on the signaling pathways required for the activation
of transcription of MMP-9 or MMP-9 mRNA stability in either cell line.
Conclusion: TSG101 bidirectionally modulates cell invasion through regulating MMP-9 mRNA expression in
different cell types. Our results provide a mechanistic context for the role of TSG101 in cell invasion as a
multifaceted gene.
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Background
Tumor susceptibility gene 101 (TSG101) was originally
defined as a tumor suppressor gene and its functional
inactivation in mouse fibroblasts produces cells with the
capacity for colony formation in 0.5 % agar and the abil-
ity to form metastatic tumors in athymic nude mice [1].
TSG101 protein contains several unique domains, such
as an inactive ubiquitin-conjugating domain, a proline-
rich region, a coiled-coil domain, and a steadiness box
[1, 2], implying diverse biological functions for TSG101
in endosomal trafficking [3–5], transcriptional regulation
[6–10], and cell proliferation [11]. Recently, TSG101 has
received attention in the field of exosome research
because of its involvement in multivesicular body forma-
tion as a component of the endosomal sorting complex
required for transport protein machinery [12–14]. Since
inactivation of TSG101 leads to a series of mitosis-
related abnormalities, TSG101 may be involved in
genome stability [15, 16]. Moreover, since inactivation of
TSG101 inhibits the endosomal trafficking of activated
EGF receptors to the lysosome and thereby results in the
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prolonged induction of downstream signaling cascades,
TSG101 may be involved in the negative regulation of re-
ceptor tyrosine kinase signaling [17, 18]. Thus, a series of
studies are shedding light on the molecular mechanism by
which TSG101 functions as a tumor suppressor gene.
However, several recent reports have also demonstrated
that TSG101 contrarily functions as a tumor-enhancing
gene in some epithelial tumor cells [19, 20], suggesting that
TSG101 may play divergent roles in carcinogenesis and
tumor progression in different cell types.
Matrix metalloproteinases (MMPs) are a family of
zinc-dependent proteolytic enzymes that degrade the
extracellular matrix (ECM) [21]. This gene family con-
sists of 23 members in human and is subdivided into
two types: soluble MMPs and transmembrane-type
MMPs. Most soluble MMPs are secreted from the cells
as inactive zymogens that are activated on the cell
membrane surface. Transmembrane-type MMPs are
anchored to the cell membrane where they degrade the
ECM and activate other MMPs. MMP activity is tightly
regulated at the levels of transcription, activation of
proenzymes by post-translational processes, and inhib-
ition by endogenous proteins, i.e., tissue inhibitors of
metalloproteinases (TIMP) [22]. However, in tumor in-
vasion, excessive activity of MMPs breaks down the
surrounding ECM microstructure, especially the base-
ment membrane barrier, and thereby contributes to the
invasion and migration of tumor cells [23–26]. Several
studies have shown that among the many MMPs, gela-
tinases, especially MMP-2 and MMP-9, play a key role
in degradation of type IV collagen, a major structural
protein for the basement membrane barrier [27, 28].
Furthermore, an increase in expression of MMP-2 and
MMP-9 has been reported in many human tumors in-
cluding neuroblastoma and melanoma [29, 30]. MMP-2
is constitutively expressed in diverse cell types [31, 32].
In contrast, in most human tumors, MMP-9 expression
is basally low but upregulated in response to diverse
growth factors and cytokines [31–34]. Accumulating
evidence suggests that the upregulation of MMP-9
expression contributes to the development of tumor
progression such as invasion, metastasis, and angiogen-
esis [23, 26]. MMP-9 expression is regulated at several
levels including gene transcription, mRNA stability, and
translation [35–37]. A number of signaling pathways
including the PKC, ERK, p38 kinase, JNK, PI3-K/Akt,
and NF-κB signaling pathways are involved in the regu-
lation of MMP-9 expression by various stimuli [38–45].
In this study, we observed that TSG101 depletion bidirec-
tionally modulated cell invasion but not cell migration in
different cell types. Among various molecules involved in
cell invasion, we suspected that MMPs would be potential
targets of TSG101 and used RNA interference (RNAi) to
examine whether TSG101 depletion affects the expression
of MMP-2 and MMP-9. We found that the regulation of
cell invasion by TSG101 through modulating MMP-9
mRNA expression was bidirectional and multifaceted, and
our findings unraveled a novel aspect of the functions of
TSG101 in cell invasion as a multifaceted gene.
Methods
Cells, antibodies, and reagents
HT1080 and U2OS cells were purchased from the
ATCC. HeLaS3 cells were a kind gift from Dr. Kishida
(Kagoshima University Graduate School of Medical and
Dental Sciences). HT1080 cells were grown in a humidi-
fied atmosphere of 5 % CO2 and 95 % air in Eagle’s
minimal essential medium supplemented with 10 % fetal
calf serum (FCS) (Invitrogen Corp., Carlsbad, CA, USA),
100 units/ml penicillin, and 100 mg/ml streptomycin at
37 °C. HeLaS3 and U2OS cells were grown in a humidi-
fied atmosphere of 5 % CO2 and 95 % air in Dulbecco’s
modified Eagle’s medium supplemented with 10 % FCS
(Invitrogen Corp.), 100 units/ml penicillin, and 100 mg/
ml streptomycin at 37 °C. An anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody was pur-
chased from MBL (Nagoya, Japan). Anti-MMP-9 and
anti-TSG101 antibodies were purchased from Abcam
(Cambridge, MA). Anti-Akt, anti-phospho-Akt (Ser473),
anti-p38, anti-phospho-p38 (Thr180/Tyr182), anti-JNK,
anti-phospho-JNK (Thr183/Tyr185), anti-NF-κB p65,
anti-phospho-NF-κB p65 (Ser536), and anti-I-κB-α anti-
bodies were purchased from Cell Signaling Technology
(Danvers, CA). Anti-ERK and anti-phospho-ERK (Thr202/
Ytr204) antibodies were purchased from BD Biosciences
(San Jose, CA). PD98059, SB203580, SP600125, and
LY294002 were purchased from Cell Signaling Technology.
MG132 and bafilomycin A1 were purchased from Calbio-
chem (San Diego, CA) and Wako Pure Chemicals (Osaka,
Japan), respectively.
Transfection
Cells were transfected with 10 nM small interfering
RNA (siRNA) targeting TSG101 or MMP-9 using RNAi
max (Invitrogen Corp.) according to the manufacturer’s
protocol. Negative control, TSG#1 (GCATGTACGTC
TTCTGTCCCGTAAA), TSG#2 (GATACCCTCCCAA
TCCCAGTGGTTA), and MMP-9 (GGAAACCCTGCC
AGTTTCCATTCAT) stealth siRNAs were purchased
from Invitrogen.
Western blotting
Cells were washed with cold phosphate buffered saline
(PBS) and lysed with a lysis buffer [50 mM Tris/HCl
pH 7.4, 150 mM NaCl, 1 × protease inhibitor cocktails
(Roche Applied Science, Basal, Switzerland), 1 × phosphat-
ase inhibitor mixture (Calbiochem), and 1 % NP-40] on
ice for 10 min. Cell lysates were clarified by centrifugation
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at 10,000 × g for 10 min at 4 °C, and the supernatants were
collected for western blotting. Protein lysate concentration
was determined using the DC protein assay kit (Bio-Rad,
Hercules, CA). The supernatants were separated by SDS-
PAGE. Western blotting was performed using the ECL-
Plus immunoblotting detection system (GE Healthcare UK
Ltd., Amersham Place, England) in accordance with the
manufacturer’s instructions. The relative density of each
immunoreactive band was quantified using LAS-1000 plus
gel documentation system (Fuji Film Co., Fuji, Japan).
Wound-healing assay
Confluent cells were serum starved for 16 h prior to
being carefully scratched using a 10 μl pipette tip. The
cellular debris was subsequently removed by washing
with PBS, and the cells were incubated in fresh serum-
free medium containing or not 200 nM phorbol 12-
myristate 13-acetate (PMA) (Sigma-Aldrich, St. Louis,
MO). The cultures were photographed at 0, 3, or 9 h to
monitor the migration of cells into the wounded area,
and the width of the wounds is expressed as a percent-
age of the initial width at zero time.
Invasion assay
At 48 and 24 h post-transfection, HT1080 and HeLaS3
cells, respectively, were trypsinized to detach cells from
the culture dish, resuspended in medium containing
10 % FCS, washed twice with serum-free medium, and
resuspended in serum-free medium containing 0.1 %
bovine serum albumin (BSA). Invasion assays were then
performed using BioCoat Matrigel Invasion Chambers
(Corning Life Sciences, Tewksbury, MA) according to
the manufacturer’s instructions. Briefly, cells (2.5 × 10 4
cells) suspended in 0.5 ml of serum-free medium con-
taining 0.1 % BSA were added to the upper chamber of
Matrigel-coated filter inserts, and 0.75 ml of fresh
medium containing 10 % FCS was added to the bottom
well as a chemoattractant. The chambers were then in-
cubated for 18 or 72 h. In assays using HeLaS3 cells, the
cells in the upper chamber were treated with 200 nM
PMA during the assay. After incubation, migrated cells
on the underside of the filter were fixed and stained with
20 % (vol/vol) methanol containing 0.1 % (wt/vol) crystal
violet powder for 5 min at room temperature. After
extensive washing in PBS, the filters were photographed
to count the number of migrated cells on the underside
in 30 randomly selected fields.
Gelatin zymography
At 32 h post-transfection, cells were serum starved for
16 h prior to being incubated in fresh serum-free
medium containing the indicated reagents for further 7
or 24 h. To measure MMP activities in conditioned
media, conditioned media were collected, cleared by
centrifugation, normalized to cell number, mixed with
non-reducing Laemmli’s sample buffer, and subjected to
electrophoresis in a 10 % SDS-PAGE gel containing
0.1 % (wt/vol) gelatin. To measure MMP activities in
cells, cells were washed with cold PBS twice and lysed in
a lysis buffer [50 mM Tris/HCl pH 7.4, 150 mM NaCl,
1 × protease inhibitor cocktails (Roche Applied Science),
1 × phosphatase inhibitor mixture (Calbiochem), and
1 % NP-40] on ice for 10 min. Cell lysates were clarified
by centrifugation at 10,000 × g for 10 min at 4 °C and
the supernatant was collected. Protein lysate concentra-
tion was determined using the DC protein assay kit
(Bio-Rad). The collected supernatant was mixed with
non-reducing Laemmli’s sample buffer, followed by elec-
trophoresis in a 10 % SDS-PAGE gel containing 0.1 %
(wt/vol) gelatin. After electrophoresis, the gels were in-
cubated in a renaturing buffer (2.5 % Triton X-100) with
gentle agitation for 1 h at 22 °C, washed with distilled
water three times, and incubated in a developing buffer
(50 mM Tris/HCl pH 7.4, 150 mM NaCl, and 10 mM
CaCl 2) for 24 h at 37 °C to allow digestion of the gel-
atin. Finally, the gels were stained with Coomassie bril-
liant blue and destained in 45 % (vol/vol) methanol and
1 % (vol/vol) acetic acid to remove excess dye. The rela-
tive density of each gelatinolytic band was quantified
using LAS-1000 plus gel documentation system (Fuji
Film Co.).
Reverse transcription (RT)-PCR
Total cellular RNA was isolated from cells using
NucleoSpin RNA II (Takara, Shiga, Japan) according to
the manufacturer’s instructions. Quantitative RT-PCR
was performed using a light cycler nano (Roche Applied
Science). Forward and reverse primers were as follows:
human MMP-2, CCCCAAAACGGACAAAGAG and C
TTCAGCACAAACAGGTTGC; human MMP-9, GAA
CCAATCTCACCGACAGG and GCCACCCGAGTGT
AACCATA; human MMP-14, GCCTTGGACTGTCAG
GAATG and AGGGGTCACTGGAATGCTC; human
TIMP-1, CTGTTGTTGCTGTGGCTGAT and AACT
TGGCCCTGATGACG; human TIMP-2, GAAGAGCC
TGAACCACAGGT and CGGGGAGGAGATGTAGC
AC; human GAPDH; CCTGTTCGACAGTCAGCCG
and CGACCAAATCCGTTGACTCG; and human 18S
rRNA; GCAATTATTCCCCATGAACG and GGGA
CTTAATCAACGCAAGC.
Analysis of mRNA turnover
HT1080 cells were switched to fresh serum-free medium
containing 1 μg/ml actinomycin D (Sigma-Aldrich) to
inhibit transcription at 48 h post-transfection. HeLaS3
cells were pre-treated with 200 nM PMA for 24 h to
promote accumulation of MMP-9 mRNA at 24 h post-
transfection and subsequently switched to fresh serum-
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free medium containing 1 μg/ml actinomycin D to
inhibit transcription. Samples were collected starting
30 min after actinomycin D treatment and at the indi-
cated periods of time. Samples were assayed for MMP-9
mRNA and 18S rRNA mRNA levels by RT-PCR.
MTT assay
Cells were seeded into a 96-well plate at a density of 2 ×
10 3 cells/well in triplicates. At 24, 48, and 72 h after
transfection, 10 μl of MTT solution (Dojindo, Kumamoto,
Japan) was added into each well. After incubation at 37 °C
for 2 h, the OD at 450 nm was analyzed on a plate reader.
Statistical analysis
Each experiment was independently repeated at least
three times. The student’s t-test was used to determine
the statistical significance of the value differences be-
tween experimental and control groups. Values of p less
than 0.05 were considered significant.
Results
TSG101 depletion promotes cell invasion of HT1080 cells
To explore the roles of TSG101 as a tumor susceptibility
gene, we used RNAi to examine whether TSG101 is
involved in tumor cell biological behaviors such as
migration and invasion in HT1080 fibrosarcoma cells.
Western blot analysis confirmed that targeted knock-
down of TSG101 led to decreased levels of TSG101
expression (Fig. 1a). First, we examined the effect of
TSG101 depletion on cell migration using a wound heal-
ing assay and found that depletion of TSG101 using
TSG#1 or TSG#2 siRNA duplexes had no impact on cell
migration (Fig. 1b, c). Next, we examined the effect of
TSG101 depletion on cell invasion using a Transwell
invasion assay. Depletion of TSG101 using TSG#1 or
TSG#2 siRNA duplexes led to increased numbers of
migrated cells on the underside of the filter (Fig. 1d, e),
suggesting that TSG101 is involved in cell invasion of
HT1080 cells.
TSG101 depletion leads to increased levels of MMP-9
expression in HT1080 cells
Gelatinases such as MMP-2 and MMP-9 play a crucial
role in tumor cell aggressiveness such as invasion and
metastasis [27–30]. We first used gelatin zymography to
examine whether TSG101 is involved in secretion and
expression of these MMPs in HT1080 cells. Depletion of
TSG101 using TSG#1 or TSG#2 siRNA duplexes led to
significantly increased levels of baseline MMP-9 secre-
tion but did not impact baseline MMP-2 secretion
(Fig. 2a). Stimulation of HT1080 cells by PMA induces
enhanced MMP-9 secretion and MMP-2 activation
[39, 41]. Depletion of TSG101 using TSG#1 or TSG#2
siRNA also led to significantly increased levels of PMA-
induced MMP-9 secretion, but did not affect PMA-
induced MMP-2 activation (Fig. 2a). Moreover, depletion
of TSG101 using TSG#1 or TSG#2 siRNA duplexes led to
significantly increased levels of MMP-9 expression but
not MMP-2 expression in cells regardless of treatment
with PMA (Fig. 2b). To explore whether TSG101 deple-
tion leads to increased levels of MMP-9 protein in cells,
we next performed western blotting experiments. Deple-
tion of TSG101 using TSG#1 or TSG#2 siRNA duplexes
led to significantly increased levels of MMP-9 protein at
least in PMA-treated cells (Fig. 2c). Together, these results
indicate that TSG101 depletion leads to increased MMP-9
protein levels and thereby enhances MMP-9 secretion in
HT1080 cells.
TSG101 depletion does not affect MMP-9 degradation in
HT1080 cells
At least two possibilities could explain the increased
levels of MMP-9 expression in TSG101-depleted cells:
one is inhibition of MMP-9 degradation, and the other
is enhancement of MMP-9 production. We first exam-
ined whether inhibition of proteasomal or lysosomal
degradation leads to increased levels of secretion and
expression of MMP-9 in HT1080 cells. Treatment with
proteasome inhibitor MG132 or lysosome inhibitor bafilo-
mycin A1 did not enhance MMP-9 secretion in control
cells to the levels seen in TSG101-depleted cells regardless
of treatment with PMA (Additional file 1: Figure S1A).
Moreover, treatment with these inhibitors did not increase
MMP-9 expression in control cells to the levels seen in
TSG101-depleted cells regardless of treatment with PMA
(Additional file 1: Figure S1B). The precise reason why
bafilomycin A1 inhibited MMP-9 secretion is not known.
However, since the NF-κB signaling pathway is strongly
involved in activation of MMP-9 mRNA transcripts in
HT1080 cells [43, 46] and since the proteasomal degrad-
ation of Iκ-B required for the activation of the NF-κB sig-
naling pathway is inhibited by MG132 [47], it is likely
that MG132 inhibits the NF-κB signaling pathway and
thereby inhibits MMP-9 expression, especially PMA-
induced MMP-9 expression, in both control and TSG101-
depleted cells. These results support the possibility that
TSG101 depletion enhances MMP-9 production.
TSG101 depletion enhances MMP-9 mRNA expression in
HT1080 cells
MMP-9 production is regulated at the levels of gene
transcription, mRNA stability, and translation [35–37].
We used RT-PCR to examine whether TSG101 depletion
affects MMP-9 mRNA levels in HT1080 cells. Upon
treatment with PMA, levels of MMP-9, MMP-9 inhibi-
tor TIMP-1, and MMP-2 activator MMP-14 mRNAs
were increased but those of MMP-2 and MMP-2 inhibi-
tor TIMP-2 mRNAs were slightly decreased (Fig. 3a).
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Depletion of TSG101 using TSG#1or TSG#2 siRNA du-
plexes led to significantly increased levels of MMP-9
mRNA but had little impact on mRNA levels of any
other examined molecules regardless of treatment with
PMA (Fig. 3b). Depletion of TSG101 using TSG#1
siRNA duplexes led to more increased levels of MMP-9
mRNA than that using TSG#2 siRNA duplexes, consist-
ent with the results in Fig. 2 showing that depletion of
TSG101 using TSG101#1 siRNA duplexes led to more
increased levels of secretion and expression of MMP-9
than that using TSG101#2 siRNA duplexes. These
results demonstrate that TSG101 depletion specifically
leads to significantly increased levels of MMP-9 mRNA
in HT1080 cells.
TSG101 depletion does not enhance the activities of the
signaling pathways required for MMP-9 secretion in
HT1080 cells
Stimulation of tumor cells by PMA has been reported to
lead to increased levels of MMP-9 secretion through
activating several signaling pathways [39, 41, 42], raising
the possibility that TSG101 depletion leads to increased
levels of MMP-9 secretion through amplifying these sig-
naling pathways. To evaluate this possibility, we first
Fig. 1 TSG101 depletion promotes cell invasion of HT1080 cells. a. Depletion of TSG101 by siRNA. Total cell lysates of cells transfected with control (con)
or TSG101 (TSG#1 or #2) siRNA were analyzed by western blot using the indicated antibodies. b–c. Cell migration of TSG101-depleted cells. Confluent
cells transfected with control (con) or TSG101 (TSG#1 or #2) siRNA were scratched and incubated in fresh serum-free medium for 3 h (b). Scale bars,
200 μm. Cell migration into the wound area in (b) was quantified (c). Relative migration activities of the cells transfected with TSG101 (TSG#1 or #2) siRNA
are expressed as the proportion of migration of the cells transfected with control (con) siRNA. d–e. Cell invasion of TSG101-depleted cells. Cells
transfected with control (con) or TSG101 (TSG#1 or #2) siRNA were allowed to invade for 18 h (d). Scale bars, 200 μm. Cell invasion through
the filter in (d) was quantified (e). Relative invasion activities of the cells transfected with TSG101 (TSG#1 or #2) siRNA are expressed as the
proportion of infiltration of the cells transfected with control (con) siRNA. The blots and images shown are representative of three independent experiments.
The results shown are the means ± S.D. of three independent experiments. * p < 0.05; **, p < 0.005; ns, not significant, by a Student’s t-test
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used gelatin zymography to examine the effect of
TSG101 depletion on MMP-9 secretion in the presence
or absence of chemical inhibitors of these signaling path-
ways in HT1080 cells. Treatment with the ERK inhibitor
PD98095, p38 kinase inhibitor SB203580, JNK inhibitor
SP600125, or PI3-K/Akt inhibitor LY294002 significantly
reduced PMA-induced MMP-9 secretion in both control
and TSG101-depleted cells, but did not decrease PMA-
induced MMP-9 secretion in TSG101-depleted cells to
the levels seen in control cells (Fig. 4a). Moreover, none
of these inhibitors eliminated the increase in baseline
MMP-9 secretion in TSG101-depleted cells (Fig. 4b).
Taken together with the results shown in Additional file
1: Figure S1, these results demonstrate that the ERK,
p38 kinase, JNK, PI3-K/Akt, and NF-κB signaling
pathways are involved in PMA-induced MMP-9 secre-
tion in HT1080 cells and suggest that TSG101 depletion
does not enhance any of these signaling pathways
required for PMA-induced MMP-9 secretion in HT1080
cells. To confirm this, we next performed western blot-
ting experiments with phospho-specific antibodies.
TSG101 depletion did not increase but instead slightly
reduced activations of the ERK, p38 kinase, PI3-K/Akt,
JNK, and NF-κB signaling pathways (Fig. 4c). Although
the precise reason why TSG101 depletion reduced acti-
vation of these signaling pathways is not known, it is
possible that these signaling pathways may be sup-
pressed in a compensatory manner. Together, these
results demonstrate that TSG101 depletion does not
enhance MMP-9 secretion at least through amplifying
Fig. 2 TSG101 depletion leads to increased secretion and expression of MMP-9 in HT1080 cells. a. MMP-9 secretion in TSG101-depleted cells.
b–c. MMP-9 expression in TSG101-depleted cells. Cells transfected with control (con) or TSG101 (TSG#1 or #2) siRNA were incubated in fresh
serum-free medium containing or not 200 nM PMA for 7 h. MMPs in conditioned media (a, top) and cell lysates (b, top) were measured using
gelatin zymography. The amounts of total MMP-2 (MMP-2 + active-MMP-2) and MMP-9 in the conditioned media (a, bottom) and cell lysates
(b, bottom) of PMA-treated cells were quantified and are expressed as arbitrary units. The amount of each MMP in the conditioned media and
cell lysates of the cells transfected with control (con) siRNA is individually set to 1.0. Cell lysates were analyzed by western blot using the indicated antibodies
(c, left). The amount of MMP-9 in PMA-treated cells was quantified and is expressed as arbitrary units (c, right). The amount of MMP-9 in the cells transfected
with control (con) siRNA is set to 1.0. The blots and gels shown are representative of three independent experiments. The results shown are the means ± S.D.
of three independent experiments. **, p< 0.005; ns, not significant, by a Student’s t-test
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any of these signaling pathways regardless of treatment
with PMA.
TSG101 does not affect MMP-9 mRNA stability in
HT1080 cells
Several studies have reported that post-transcriptional
mechanisms are involved in the regulation of MMP-9
mRNA levels [35, 36]. Therefore, to examine the possi-
bility that TSG101 participates in post-transcriptional
regulation of MMP-9 mRNA stability, we used an estab-
lished approach to inhibit new gene transcription and
measure MMP-9 mRNA decay over time [48]. There
was not a significant difference in level of remaining
MMP-9 or 18S rRNA mRNA at each time point between
control and TSG101-depleted cells (Additional file 2:
Figure S2A and B), suggesting that TSG101 does not
participate in post-transcriptional regulation of MMP-9
mRNA stability in HT1080 cells.
TSG101 modulates cell invasion of HT1080 cells in an
MMP-9-dependent manner
Our results strongly support the possibility that TSG101
is involved in cell invasion of HT1080 cells through
regulating MMP-9 expression. To explore this possibility,
we first examined whether MMP-9 is involved in cell inva-
sion of HT1080 cells. Western blot analysis confirmed
Fig. 3 TSG101 depletion enhances MMP-9 mRNA expression in HT1080 cells. a. MMP-related gene mRNA expression. Subconfluent cells were
serum starved for 16 h and subsequently incubated in fresh serum-free medium containing or not 200 nM PMA for 7 h. RT-PCR was performed
to examine levels of the indicated mRNAs. The ratio of each MMP-related gene mRNA level relative to the GAPDH mRNA level is expressed as
arbitraryunits. Each MMP-related gene level in non-treated cells is set to 1.0. b. MMP-related gene expression in TSG101-depleted cells. Cells
transfected with control (con) or TSG101 (TSG#1 or #2) siRNA were incubated in fresh serum-free medium containing or not 200 nM PMA for
7 h. RT-PCR was performed to examine levels of the indicated mRNAs. The ratio of each MMP-related gene mRNA level relative to the GAPDH
mRNA level is expressed as arbitrary units. Each MMP-related gene mRNA level in the cells transfected with control (con) siRNA is set to 1.0
individually in non- and PMA-treated cells. The results shown are the means ± S.D. of three independent experiments. * p < 0.05; **, p < 0.005;
ns, not significant, by a Student’s t-test
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that targeted knockdown of MMP-9 by siRNA led to de-
creased levels of MMP-9 expression (Fig. 5a). MMP-9 de-
pletion led to decreased levels of MMP-9 secretion
regardless of treatment with PMA (Fig. 5b) and moreover
led to decreased numbers of migrated cells on the under-
side of the filter (Fig. 5c. d), suggesting that MMP-9 is at
least involved in cell invasion of HT1080 cells. MMP-9 de-
pletion may partially inhibit cell invasion because MMP-2
secretion is more prominent in HT1080 cells than MMP-
9 secretion. Next we examined the effect of simultaneous
depletion of TSG101 and MMP-9 on cell invasion of
HT1080 cells. Simultaneous depletion of TSG101 and
MMP-9 reduced numbers of migrated cells on the under-
side of the filter to the levels seen in the cells treated with
MMP-9 siRNA duplexes alone (Fig. 5c, d). Taken together
with the results that depletion of neither TSG101 nor
MMP-9 affected cell growth of HT1080 cells (data not
shown), these results demonstrate that TSG101 is at least
involved in cell invasion of HT1080 cells in an MMP-9-
dependent manner.
TSG101 depletion contrarily decreases MMP-9 mRNA
expression in PMA-treated HeLaS3 cells
To explore whether TSG101 depletion has the same
effects in other cell lines as in HT1080 cells, we exam-
ined the effect of TSG101 depletion on MMP-9 mRNA
expression in U2OS osteosarcoma and HeLaS3 cervical
carcinoma cells. Western blot analysis confirmed that
targeted knockdown of TSG101 in U2OS and HeLaS3
cells by siRNA led to decreased levels of TSG101
expression (Additional file 3: Figure S3A and Fig. 6a).
TSG101 depletion exhibited the same effects on MMP-9
secretion, MMP-9 expression, and MMP-9 mRNA ex-
pression in U2OS cells (Additional file 3: Figure S3, b-e).
However, depletion of TSG101 using TSG#1 siRNA
duplexes contrarily led to decreased levels of MMP-9
Fig. 4 TSG101 depletion has little impact on the signaling pathways in PMA-stimulated HT1080 cells. Cells transfected with control (con) or
TSG101 (TSG#1) siRNA were incubated in fresh serum-free medium containing the indicated reagents. a–b. Cells were incubated with 50 μM
PD98059, 10 μM SB203580, 50 μM SP600125, or 50 μM LY294002 in fresh serum-free medium containing or not 200 nM PMA for 7 h. MMPs in
conditioned media from PMA-treated (a) and non-treated (b) cells were measured using gelatin zymography. c. Cells were incubated in fresh
serum-free medium containing 200 nM PMA for the indicated periods of time. Cell lysates were analyzed by western blot using the indicated
antibodies. The blots and gels shown are representative of three independent experiments
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secretion in PMA-treated HeLaS3 cells (Fig. 6b). More-
over, TSG101 depletion using TSG#1 siRNA duplexes
proportionally led to decreased levels of MMP-9 mRNA
in PMA-treated HeLaS3 cells (Fig. 6c). Since similar re-
sults were obtained using two sets of siRNA duplexes
(TSG#1 and #2), it is not likely that the decrease in
MMP-9 secretion and MMP-9 mRNA expression in
PMA-treated cells is due to the off-target effect of
siRNA treatment. Moreover, depletion of TSG101 using
TSG#1 siRNA duplexes more effectively led to decreased
levels of MMP-9 mRNA than that using TSG#2 siRNA
duplexes, consistent with the results in Fig. 6b showing
that depletion of TSG101 using TSG#1 siRNA duplexes
more effectively led to decreased levels of MMP-9 secre-
tion than that using TSG#2 siRNA duplexes. Together,
these results raise the possibility that TSG101 might bi-
directionally modulate cell invasion through regulating
MMP-9 mRNA expression.
TSG101 depletion reduces cell invasion of HeLaS3 cells
We next examined whether TSG101 depletion affects
cell migration and cell invasion of HeLaS3 cells. Since
the effect of TSG101 depletion on MMP-9 secretion in
HeLaS3 cells was observed in the presence of PMA, the
following experiments were performed in the presence
of PMA. Depletion of TSG101 using TSG#1 or TSG#2
siRNA duplexes had no impact on cell migration of
PMA-treated HeLaS3 cells (Fig. 6d, e). On the other
hand, depletion of TSG101 using TSG#1 or TSG#2 siRNA
duplexes led to decreased numbers of migrated PMA-
treated cells on the underside of the filter (Fig. 6f, g).
MMP-9 depletion using MMP-9 siRNA duplexes led to
decreased numbers of migrated PMA-treated cells on the
underside of the filter (Fig. 6f, g), suggesting that MMP-9
is also involved in cell invasion of HeLaS3 cells. Taken
together with the results that depletion of neither TSG101
nor MMP-9 affected cell growth of HeLaS3 cells (data not
shown), these results suggest that TSG101 may be impli-
cated in the invasive potency of HeLaS3 cells as a tumor-
enhancing gene.
TSG101 depletion does not reduce the activities of the
signaling pathways required for MMP-9 secretion in
HeLaS3 cells
To explore the mechanism underlying decreased levels
of PMA-induced MMP-9 mRNA in TSG101-depleted
Fig. 5 TSG101 modulates cell invasion of HT1080 cells in an MMP-9-dependent manner. Cells were transfected with control (con) or MMP-9 siRNA
to deplete MMP-9, or with TSG101 (TSG#2) siRNA and control (con) or MMP-9 siRNA to simultaneously deplete TSG101 and MMP-9. a–b. Expression
and secretion of MMP-9 in simultaneous TSG101- and MMP-9-depleted cells. Cells were incubated in fresh serum-free medium containing or not 200
nM PMA for 7 h. Cell lysates were analyzed by western blot using the indicated antibodies (a). MMPs in conditioned media were measured
using gelatin zymography (b). c–d. Cell invasion of simultaneous TSG101- and MMP-9-depleted cells. Each of the transfected cells was allowed
to invade for 18 h (c). Scale bars, 200 μm. Cell invasion through the filter in (c) was quantified (d). Relative invasion activities of the cells transfected with
MMP-9 siRNA alone, and TSG101 (TSG#2) siRNA and control (con) or MMP-9 siRNA are expressed as the proportion of infiltration of the cells transfected
with control (con) siRNA. The blots, gels, and images shown are representative of three independent experiments. The results shown are the means ±
S.D. of three independent experiments. * p < 0.05; **, p < 0.005; ns, not significant, by a Student’s t-test
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HeLaS3 cells, we first examined which of the signaling
pathways are involved in PMA-induced MMP-9 secretion
in HeLaS3 cells. Among various chemical inhibitors,
PD98095, SP600125, LY294002, and MG132 significantly
reduced PMA-induced MMP-9 secretion while SB203580
had no impact (Fig. 7a), suggesting that the ERK, JNK,
PI3-K/Akt, and NF-κB signaling pathways may be at least
involved in PMA-induced MMP-9 secretion in HeLaS3
cells. To explore whether TSG101 depletion inhibits
PMA-induced activation of these signaling pathways in
HeLaS3 cells, we next performed western blotting ex-
periments with phospho-specific antibodies. Although
phosphorylated NF-κB was not detected (data not
shown), we speculate that TSG101 depletion did not
affect the activation of the NF-κB pathway because
TSG101 depletion did not affect I-κB degradation
Fig. 6 TSG101 depletion decreases MMP-9 secretion and reduces cell invasion in PMA-treated HeLaS3 cells. Cells were transfected with control
(con), TSG101 (TSG#1 or #2), or MMP-9 siRNA. a. Depletion of TSG101 by siRNA. Total cell lysates were analyzed by western blot. b–c. MMP-9
secretion and MMP-9 mRNA expression in TSG101-depleted cells. Cells were incubated in fresh serum-free medium containing or not 200 nM
PMA for 24 h. MMP9 in conditioned media was measured using gelatin zymography (b, left). The amount of MMP-9 in PMA-treated cells was
quantified and is expressed as arbitrary units (b, right). The amount of MMP-9 in conditioned media of the cells transfected with control (con)
siRNA is set to 1.0. Expression levels of MMP-9 and GAPDH mRNAs in PMA-treated cells were analyzed by RT-PCR (c). The ratio of MMP-9 mRNA
level relative to the GAPDH mRNA level is expressed as arbitrary units. The MMP-9 mRNA level in the cells transfected with control (con) siRNA is
set to 1.0. d–e. Cell migration of TSG101-depleted cells. Confluent transfected cells were scratched and incubated in fresh serum-free medium
containing 200 nM PMA for 9 h (d). Scale bars, 200 μm. Cell migration into the wound area in (d) was quantified (e). Relative migration activities
of the cells transfected with TSG101 siRNA are expressed as the proportion of migration of the cells transfected with control (con) siRNA. f–g. Cell
invasion of TSG101-depleted cells. Each of the transfected cells was allowed to invade for 72 h (f). Scale bars, 200 μm. Cell invasion through the
filter in (f) was quantified (g). Relative invasion activities of the cells transfected with TSG101 or MMP-9 siRNA are expressed as the proportion of infiltration
of the cells transfected with control (con) siRNA. The blots, gels, and images shown are representative of three independent experiments. The results
shown are the means ± S.D. of three independent experiments. * p< 0.05; **, p< 0.005; ns, not significant, by a Student’s t-test
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(Fig. 7b). Moreover, TSG101 depletion did not reduce
but instead slightly enhanced activations of the p38 kin-
ase, PI3-K/Akt, and JNK signaling pathways (Fig. 7c).
Although the precise reason why TSG101 depletion
promoted activation of these signaling pathways is not
known, it is possible that these signaling pathways may
be activated in a compensatory manner. These results
suggest that TSG101 depletion does not decrease
MMP-9 secretion at least through reducing any of these
signaling pathways in PMA-treated HeLaS3 cells.
TSG101 does not affect MMP-9 mRNA stability in
HeLaS3 cells
To investigate whether TSG101 participates in post-
transcriptional regulation of MMP-9 mRNA stability in
HeLaS3 cells, we measured MMP-9 mRNA decay over
time in HeLaS3 cells. However, because of the very low
baseline levels of MMP-9 mRNA in HeLaS3 cells, it was
necessary to first induce MMP-9 mRNA to detectable
levels in these cells so that we could monitor the rate of
mRNA turnover. There was not a significant difference
in level of remaining MMP-9 or 18S rRNA mRNA at
each time point between control and TSG101-depleted
cells (Additional file 2: Figure S2C and D), suggesting
that TSG101 does not participate in post-transcriptional
regulation of MMP-9 mRNA stability in HeLaS3 cells.
Discussion
In tumor invasion, degradation of ECM proteins by
tumor cells disrupts this structure, enabling tumor cell
invasion through the matrix [49]. The ability of tumor
cells to invade into and migrate through their
Fig. 7 TSG101 depletion has little impact on the signaling pathways in PMA-stimulated HeLaS3 cells. Cells transfected with control (con) or TSG101
(TSG#1) siRNA were incubated in fresh serum-free medium containing the indicated reagents. a. Cells were incubated with 50 μM PD98059, 10 μM
SB203580, 50 μM SP600125, 50 μM LY294002, or 10 μM MG132 in fresh serum-free medium containing 200 nM PMA for 24 h. MMP-9 in conditioned
media was measured using gelatin zymography. b–c. Cells were incubated in fresh serum-free medium containing 200 nM PMA for the indicated
periods of time. Cell lysates were analyzed by western blot using the indicated antibodies. The blots and gels shown are representative of three
independent experiments
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surrounding environment is directly correlated with the
morbidity and mortality of all forms of cancer. Therefore,
the mechanism of the degradation of ECM proteins by
tumor cells has been intensively studied and evidence is
emerging showing that MMPs play a central role in ECM
degradation and cellular invasion [23–26]. Among the
MMPs, MMP-9 is thought to play a pivotal role in the
degradation of basement membrane collagen IV and
therefore may mainly contribute to the invasive ability of
various types of tumor cells [27–30]. Consistently, MMP-
9 depletion reduced cell invasion of HT1080 and HeLaS3
cells, indicating a role for MMP-9 in cell invasion. On the
basis of our present finding that TSG101 depletion pro-
moted cell invasion and MMP-9 expression in HT1080
cells, but contrarily reduced these events in HeLaS3 cells,
TSG101 may be implicated in the invasive potency of
tumor cells through regulating the expression of MMP-9.
As expected, the enhancement of cell invasion by TSG101
depletion was attenuated by simultaneous depletion of
MMP-9 in HT1080 cells. Together, these data suggested
that TSG101 participates in cell invasion in an MMP-9-
dependent manner.
The expression and secretion of MMP-9 is regulated at
several levels: transcription, mRNA stability, translation,
protein degradation, and protein secretion [35–37]. We
found that TSG101 depletion increased the levels of
MMP-9 mRNA in HT1080 and U2OS cells, but contrarily
decreased the levels of MMP-9 mRNA in HeLaS3 cells,
and we also found that TSG101 depletion did not affect
MMP-9 mRNA stability in either HT1080 or HeLaS3
cells. We did not explore the effect of TSG101 depletion
on MMP-9 translation. However, since changes in MMP-
9 protein levels were proportional to those in MMP-9
mRNA levels in TSG101-depleted cells, we speculate that
TSG101 depletion does not affect this step. Together, our
present results suggest that TSG101 might bidirectionally
modulate the transcription of MMP-9 gene in different
cell types.
The promoter of the human MMP-9 gene contains
multiple functional cis-regulatory elements including
AP-1, NF-κB, Sp-1, Ets-1, and Egr-1 elements, which are
involved in baseline and induced transcriptional re-
sponses [43, 46, 50]. Several studies have shown that the
transcription of MMP-9 is activated by several signaling
pathways via these elements [40, 42, 50]. On the basis of
our present finding that TSG101 depletion had little
impact on any signaling pathways involved in PMA-
induced MMP-9 secretion, it is not likely that TSG101
modulates the activities of the signaling pathways re-
quired for MMP-9 secretion. We have not yet elucidated
the precise mechanism by which TSG101 participates in
regulation of the transcription of MMP-9. However,
TSG101 may directly or indirectly modulate the tran-
scription of MMP-9 in the nucleus, based on the
following observations. Previous reports showed that
TSG101 acts as a transcriptional modulator to affect nu-
clear hormone receptor-mediated transcriptional activa-
tion [6, 9] and demonstrated that TSG101 interacts with
and downregulates the promoter of p21, a tumor sup-
pressor gene [7]. In synchronized cell lines, TSG101 is
present in both the nucleus and Golgi complex during
interphase, dispersed more generally throughout the
cytoplasm in late S phase, and enriched in mitotic spin-
dles and centrosomes during mitosis [15], implying that
TSG101 plays diverse roles in both nucleus and
cytoplasm.
The functions of TSG101 in carcinogenesis and tumor
progression have been controversial. Besides cell inva-
sion, we found that TSG101 depletion did not affect cell
growth or cell migration of HT1080 or HeLaS3 cells,
although it was reported that TSG101 depletion inhibits
cell growth and cell migration of prostate cancer PC3,
breast cancer MDA-MB-231, and breast cancer MCF-7
cells [19, 20]. We were unable to clarify the reason why
TSG 101 depletion had no impact on cell growth or cell
migration of HT1080 or HeLaS3 cells, but expect that
the unprecedented link between TSG101 function and
MMP-9 mRNA expression provides a clue to reveal the
mechanism underlying the controversial functions of
TSG101 in carcinogenesis and tumor progression. Further
studies to unravel the precise mechanism by which
TSG101 bidirectionally modulates the transcription of
MMP-9 are necessary. Furthermore, we conceive that
there may be a difference in pathological roles of TSG101
between tumor cell types derived from epithelial and mes-
enchymal tissues. TSG101 was originally identified as a
tumor suppressor gene in mouse fibroblasts. HT1080 and
U2OS cells, of which TSG101 depletion promoted cell in-
vasion and increased MMP-9 expression, are derived from
mesenchymal tissues. On the other hand, HeLaS3 cells, of
which TSG101 depletion reduced cell invasion and
decreased MMP-9 expression, are derived from epithelial
tissues. PC3, MDA-MB-231, and MCF-7 cells, where
TSG101 has been reported to function as a tumor-
enhancing gene, are derived from epithelial tissues. More-
over, it has been recently reported that positive TSG101
expression is significantly associated with invasion of
adenocarcinoma of the gallbladder [51]. Although further
studies are necessary, TSG101 may play pathological roles
as a tumor-enhancing gene in tumor cell types derived
from epithelial tissues.
Conclusion
In summary, we found that TSG101 bidirectionally mod-
ulated cell invasion through regulating MMP-9 mRNA
expression in different cell types. TSG101, which was
initially identified as a tumor suppressor gene, is also
known to contrarily function as a tumor-enhancing gene
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[1]. To the best of our knowledge, our present findings
are the first report providing a new insight into a puta-
tive mechanism by which TSG101 bidirectionally partici-
pates in carcinogenesis and tumor progression as a
multifaceted gene in different cell types.
Additional files
Additional file 1: Figure S1. TSG101 depletion does not affect MMP-9
degradation in HT1080 cells. Cells transfected with control (con) or
TSG101 (TSG#1) siRNA were incubated with 10 μM MG132 or 100 nM
bafilomycin A1 (BafA1) in fresh serum-free medium containing or not 200
nM PMA for 7 h. MMPs in conditioned media (A) and cell lysates (B) were
measured using gelatin zymography. The gels shown are representative
of three independent experiments. (PDF 1033 kb)
Additional file 2: Figure S2. TSG101 depletion does not affect MMP-9
mRNA stability in either HT1080 or HeLaS3 cells. Stability of MMP-9 mRNA
in TSG101-depleted HT1080 cells (A and B) and TSG101-depleted HeLaS3
cells (C and D). Cells transfected with control or TSG101 (TSG#1) siRNA
were incubated in fresh serum-free medium containing 1 μg/ml actinomycin
D for various time points and RT-PCR was performed to monitor turnover of
MMP-9 mRNA. Expression levels of MMP-9 (A and C) and 18S rRNA (B and D)
mRNAs were analyzed by RT-PCR. Results are plotted as the percentage of
mRNA remaining relative to the starting amounts at 0 h individually in control
and TSG101 (TSG#1) siRNA transfected cells. The results shown are the
means ± S.D. of three independent experiments. Ns, not significant, by
Student’s t-test. (PDF 351 kb)
Additional file 3: Figure S3. TSG101 depletion leads to increased levels
of MMP-9 mRNA in U2OS cells. (A) Depletion of TSG101 by siRNA. Total
cell lysates of cells transfected with control (con) or TSG101 (TSG#1) siRNA
were analyzed by western blot using the indicated antibodies. (B) and (C)
Secretion and expression of MMP-9 in TSG101-depleted cells. Cells
transfected with control (con) or TSG101 (TSG#1) siRNA were incubated
in fresh serum-free medium containing or not 200 nM PMA for 7 h.
MMPs in conditioned media (B) and cell lysates (C) were measured
using gelatin zymography. (D) MMP-9 mRNA expression in PMA-treated
cells. Subconfluent cells were serum starved for 16 h and subsequently
incubated in fresh serum-free medium containing or not 200 nM PMA
for 7 h. Expression levels of MMP-9 and GAPDH mRNAs were analyzed
by RT-PCR. The ratio of MMP-9 mRNA level relative to the GAPDH mRNA
level is expressed as arbitrary units. MMP-9 mRNA level in non-treated cells
is set to 1.0. (E) MMP-9 mRNA expression in TSG101-depleted cells. Cells
transfected with control (con) or TSG101 (TSG#1) siRNA were incubated in
fresh serum-free medium containing or not 200 nM PMA for 7 h. The ratio
of MMP-9 mRNA level relative to the GAPDH mRNA level is expressed as
arbitrary units. MMP-9 mRNA level in the cells transfected with control (con)
siRNA is set to 1.0 individually in non- and PMA-treated cells. The blots and
gels shown are representative of three independent experiments. The
results shown are means ± S.D. of three independent experiments. **,
p < 0.005, by a Student’s t-test. (PDF 592 kb)
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